These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 24169101

  • 1. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results.
    Petrarca R, Dugel PU, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.
    Retina; 2014 May; 34(5):874-9. PubMed ID: 24169101
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography.
    Petrarca R, Dugel PU, Nau J, Slakter JS, Jaffe GJ, Jackson TL.
    Ophthalmology; 2013 Feb; 120(2):328-33. PubMed ID: 23178157
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL, Soare C, Petrarca C, Simpson A, Neffendorf JE, Petrarca R, Muldrew A, Peto T, Chakravarthy U, Membrey L, Haynes R, Costen M, Steel D, Desai R, MERLOT Study Group.
    JAMA Ophthalmol; 2020 Aug 01; 138(8):835-842. PubMed ID: 32644148
    [Abstract] [Full Text] [Related]

  • 6. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
    Jackson TL, Dugel PU, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA, CABERNET Study Group.
    Ophthalmology; 2013 Aug 01; 120(8):1597-603. PubMed ID: 23490325
    [Abstract] [Full Text] [Related]

  • 7. Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial.
    Jackson TL, Desai R, Simpson A, Neffendorf JE, Petrarca R, Smith K, Wittes J, Lewis C, Membrey L, Haynes R, Costen M, Steel DH, Muldrew A, Chakravarthy U, Macular Epiretinal Brachytherapy versus Ranibizumab (Lucentis) Only Treatment (MERLOT) Study Group.
    Ophthalmology; 2016 Jun 01; 123(6):1287-96. PubMed ID: 27086023
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes.
    Morales-Canton V, Quiroz-Mercado H, Velez-Montoya R, Zavala-Ayala A, Moshfeghi AA, Shusterman EM, Kaiser PK, Sanislo SR, Gertner M, Moshfeghi DM.
    Am J Ophthalmol; 2013 Jun 01; 155(6):1000-1008.e2. PubMed ID: 23497847
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. One-year results from clinical practice of epimacular strontium-90 brachytherapy for the treatment of subfoveal choroidal neovascularization secondary to AMD.
    Zur D, Loewenstein A, Barak A.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar 01; 46(3):338-43. PubMed ID: 25856820
    [Abstract] [Full Text] [Related]

  • 12. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov 01; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 13. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS, Daftari I, Phillips T, Morse LS.
    Retina; 2012 May 01; 32(5):956-66. PubMed ID: 22183743
    [Abstract] [Full Text] [Related]

  • 14. 24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes.
    Canton VM, Quiroz-Mercado H, Velez-Montoya R, Lopez-Miranda MJ, Moshfeghi AA, Shusterman EM, Kaiser PK, Sanislo SR, Gertner M, Moshfeghi DM.
    Ophthalmic Surg Lasers Imaging; 2012 May 01; 43(1):20-4. PubMed ID: 22251841
    [Abstract] [Full Text] [Related]

  • 15. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
    Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM, INTREPID Study Group.
    Ophthalmology; 2013 Sep 01; 120(9):1893-900. PubMed ID: 23490327
    [Abstract] [Full Text] [Related]

  • 16. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM, Chen E, Mariani A, Major JC, SAVE Study Group.
    Ophthalmology; 2013 Feb 01; 120(2):349-54. PubMed ID: 23131717
    [Abstract] [Full Text] [Related]

  • 17. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration.
    Ranchod TM, Ray SK, Daniels SA, Leong CJ, Ting TD, Verne AZ.
    Retina; 2013 Sep 01; 33(8):1600-4. PubMed ID: 23549100
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, VIEW 1 and VIEW 2 Study Groups.
    Ophthalmology; 2012 Dec 01; 119(12):2537-48. PubMed ID: 23084240
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.